Pfizer Inc. — China registrations and re-registration filing lines
15 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest filing line: 2026-10-07.
| Approval number | Product | Certificate expires | Filing line (Art. 82) |
|---|---|---|---|
| 国药准字HJ20220029 | CIBINQO 阿布昔替尼片 | 2027-04-07 | 2026-10-07 |
| 国药准字HJ20220030 | CIBINQO 阿布昔替尼片 | 2027-04-07 | 2026-10-07 |
| 国药准字HJ20220031 | CIBINQO 阿布昔替尼片 | 2027-04-07 | 2026-10-07 |
| 国药准字HJ20130830 | Zithromax 注射用阿奇霉素 | 2028-07-03 | 2028-01-03 |
| 国药准字HJ20130831 | Zithromax 注射用阿奇霉素 | 2028-07-03 | 2028-01-03 |
| 国药准字HJ20140685 | Zithromax 注射用阿奇霉素 | 2028-07-03 | 2028-01-03 |
| 国药准字HJ20230118 | LITFULO 甲苯磺酸利特昔替尼胶囊 | 2028-10-17 | 2028-04-17 |
| 国药准字HJ20240004 | NURTEC 硫酸瑞美吉泮口崩片 | 2029-01-22 | 2028-07-22 |
| 国药准字HJ20150360 | Glucotrol XL 格列吡嗪控释片 | 2029-10-13 | 2029-04-13 |
| 国药准字HJ20150361 | Glucotrol XL 格列吡嗪控释片 | 2029-10-13 | 2029-04-13 |
| 国药准字HJ20160139 | Glucotrol XL 格列吡嗪控释片 | 2029-10-13 | 2029-04-13 |
| 国药准字HJ20160140 | Glucotrol XL 格列吡嗪控释片 | 2029-10-13 | 2029-04-13 |
| 国药准字SJ20250010 | ELREXFIO 埃纳妥单抗注射液 | 2030-03-03 | 2029-09-03 |
| 国药准字SJ20250011 | ELREXFIO 埃纳妥单抗注射液 | 2030-03-03 | 2029-09-03 |
| 国药准字HJ20210071 | Tofacitinib Citrate Sustained-release Tablets 枸橼酸托法替布缓释片 | 2031-05-05 | 2030-11-05 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.